600332 白云山
午间休市 01-15 11:29:59
资讯
新帖
简况
1月14日白云山发生1笔大宗交易 成交金额243.97万元
证券之星 · 01-14 17:33
1月14日白云山发生1笔大宗交易 成交金额243.97万元
白云山：公司始终以研发创新作为重点发展战略之一
证券日报 · 01-12 21:06
白云山：公司始终以研发创新作为重点发展战略之一
每周股票复盘：白云山（600332）H股与A股股份及股本均无变动
证券之星 · 01-11
每周股票复盘：白云山（600332）H股与A股股份及股本均无变动
LSV Asset Management增持白云山(00874)3万股 每股作价约18.11港元
智通财经网 · 01-07
LSV Asset Management增持白云山(00874)3万股 每股作价约18.11港元
每周股票复盘：白云山（600332）注射用头孢呋辛钠通过一致性评价
证券之星 · 01-02
每周股票复盘：白云山（600332）注射用头孢呋辛钠通过一致性评价
白云山附属企业广药二期基金正式签约设立广药荔湾基金
中金财经 · 01-01
白云山附属企业广药二期基金正式签约设立广药荔湾基金
白云山：2025年第三次临时股东会决议公告
证券日报 · 2025-12-30
白云山：2025年第三次临时股东会决议公告
白云山(00874)：附属广药二期基金与广药资本、广开基金订立设立广药广开基金的合伙协议一
智通财经 · 2025-12-29
白云山(00874)：附属广药二期基金与广药资本、广开基金订立设立广药广开基金的合伙协议一
白云山最新公告：分公司白云山制药总厂注射用头孢呋辛钠通过仿制药一致性评价
证券之星 · 2025-12-29
白云山最新公告：分公司白云山制药总厂注射用头孢呋辛钠通过仿制药一致性评价
每周股票复盘：白云山（600332）子公司获狂犬病疫苗注册证
证券之星 · 2025-12-28
每周股票复盘：白云山（600332）子公司获狂犬病疫苗注册证
白云山最新公告：旗下生物制品公司获冻干人用狂犬病疫苗注册证书
证券之星 · 2025-12-25
白云山最新公告：旗下生物制品公司获冻干人用狂犬病疫苗注册证书
白云山：第九届董事会第三十二次会议决议公告
证券日报 · 2025-12-22
白云山：第九届董事会第三十二次会议决议公告
白云山 - 子公司出资人民币9950万元参与建立GP荔湾基金
美股速递 · 2025-12-22
白云山 - 子公司出资人民币9950万元参与建立GP荔湾基金
白云山 - 参与设立广开基金和荔湾基金
美股速递 · 2025-12-22
白云山 - 参与设立广开基金和荔湾基金
白云山最新公告：附属企业拟投资9750万元认购广药广开基金有限合伙份额
证券之星 · 2025-12-22
白云山最新公告：附属企业拟投资9750万元认购广药广开基金有限合伙份额
白云山 - 旗下单位将以5.005亿人民币收购浙江医药产业100%股权
美股速递 · 2025-12-17
白云山 - 旗下单位将以5.005亿人民币收购浙江医药产业100%股权
白云山（600332）披露控股子公司拟开展应收账款资产证券化业务，12月17日股价上涨0.12%
证券之星 · 2025-12-17
白云山（600332）披露控股子公司拟开展应收账款资产证券化业务，12月17日股价上涨0.12%
白云山最新公告：子公司广州医药拟5.005亿元收购浙江医工100%股权
证券之星 · 2025-12-17
白云山最新公告：子公司广州医药拟5.005亿元收购浙江医工100%股权
小摩减持白云山(00874)11.2万股 每股作价18.581港元
智通财经网 · 2025-12-15
小摩减持白云山(00874)11.2万股 每股作价18.581港元
白云山（600332）披露子公司《药品生产许可证》注销公告，12月15日股价下跌1.31%
中金财经 · 2025-12-15
白云山（600332）披露子公司《药品生产许可证》注销公告，12月15日股价下跌1.31%
加载更多
公司概况
公司名称：
广州白云山医药集团股份有限公司
所属行业：
医药制造业
上市日期：
2001-02-06
主营业务：
广州白云山医药集团股份有限公司的主营业务是中西成药、化学原料药、天然药物、生物医药、化学原料药中间体的研发、制造与销售；西药、中药和医疗器械的批发、零售和进出口业务；大健康产品的研发、生产与销售；医疗服务、健康管理、养生养老等健康产业投资。公司的主要产品是中成药、化学药。
发行价格：
9.80
{"stockData":{"symbol":"600332","market":"SH","secType":"STK","nameCN":"白云山","latestPrice":25.15,"timestamp":1768447799000,"preClose":25.1,"halted":0,"volume":5658535,"delay":0,"changeRate":0.002,"floatShares":1406000000,"shares":1626000000,"eps":1.837,"marketStatus":"午间休市","change":0.05,"latestTime":"01-15 11:29:59","open":25.1,"high":25.2,"low":25.04,"amount":142000000,"amplitude":0.0064,"askPrice":25.15,"askSize":271,"bidPrice":25.14,"bidSize":138,"shortable":0,"etf":0,"ttmEps":1.837,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768453200000},"marketStatusCode":3,"adr":0,"adjPreClose":25.1,"symbolType":"stock","openAndCloseTimeList":[[1768440600000,1768447800000],[1768453200000,1768460400000]],"highLimit":27.61,"lowLimit":22.59,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1625790949,"isCdr":false,"pbRate":1.08,"roa":"--","peRate":13.6908,"roe":"8.88%","epsLYR":1.744,"committee":0.043246,"marketValue":40889000000,"turnoverRate":0.004,"status":0,"hkstockBrief":{"symbol":"00874","market":"HK","secType":"STK","nameCN":"白云山","latestPrice":18.65,"timestamp":1768449900002,"preClose":18.68,"halted":0,"volume":268000,"delay":0,"premium":"-33.73"},"floatMarketCap":35358000000},"requestUrl":"/m/hq/s/600332","defaultTab":"news","newsList":[{"id":"2603918706","title":"1月14日白云山发生1笔大宗交易 成交金额243.97万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603918706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603918706?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:33","pubTimestamp":1768383222,"startTime":"0","endTime":"0","summary":"证券之星消息，1月14日白云山发生大宗交易，交易数据如下：大宗交易成交价格25.1元，成交9.72万股，成交金额243.97万元，买方营业部为东方证券股份有限公司上海黄浦区中华路证券营业部，卖方营业部为东方证券股份有限公司上海黄浦区中华路证券营业部。近三个月该股共发生3笔大宗交易，合计成交4566.0手。截至2026年1月14日收盘，白云山报收于25.1元，下跌0.79%，换手率1.55%，成交量21.84万手，成交额5.51亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400029791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600332","00874","BK0096","BK1515","BK1606","BK1521","BK0070","BK1197","BK0097","BK0012","BK0028","BK0196","BK0239","BK0175","BK0183","BK1191"],"gpt_icon":0},{"id":"2602510441","title":"白云山：公司始终以研发创新作为重点发展战略之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510441","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602510441?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:06","pubTimestamp":1768223170,"startTime":"0","endTime":"0","summary":"证券日报网讯1月12日，白云山在互动平台回答投资者提问时表示，公司始终以研发创新作为重点发展战略之一。目前在研1类创新药有十余项，公司已披露的在研项目主要有选择性RET小分子抑制剂BYS10片、用于膝骨关节炎的BYS30颗粒、养阴舒肝颗粒、LBZ-18、LBZ-18口服乳等，具体内容可查阅公司已披露的相关公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601123616044971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK1197","BK1521","BK0196","00874","BK0028","BK0183","BK0070","BK0188","BK1606","BK0012","BK0097","BK0096","BK1515","600332","BK0239","BK1191"],"gpt_icon":0},{"id":"2602053588","title":"每周股票复盘：白云山（600332）H股与A股股份及股本均无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2602053588","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602053588?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:17","pubTimestamp":1768069027,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，白云山报收于25.32元，较上周的25.74元下跌1.63%。本周关注点公司公告汇总：H股与A股股份及股本均无变动公司公告汇总：库存股数目为零公司公告汇总H股公告广州白云山医药集团股份有限公司截至2025年12月31日的证券变动月报表显示，公司普通股H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股上月底结存及本月底结存均为219,900,000股，A股上月底结存及本月底结存均为1,405,890,949股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","600332","BK1521","BK0070","BK0239","BK0196","BK0097","BK0096","BK0188","BK1191","159982","BK1197","BK0012","BK0183","BK1606","BK0028","00874","399300","BK1515"],"gpt_icon":0},{"id":"2601246872","title":"LSV Asset Management增持白云山(00874)3万股 每股作价约18.11港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601246872","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601246872?lang=zh_cn&edition=full","pubTime":"2026-01-07 18:56","pubTimestamp":1767783399,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，1月5日，LSV Asset Management增持白云山(00874)3万股，每股作价18.112港元，总金额约为54.34万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260107/20260107185713_55074.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260107/20260107185713_55074.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1515","BK0097","BK0028","BK0175","BK0188","BK0183","BK0012","600332","BK0070","BK0096","00874","BK0239","BK1521","BK1191","BK1606","BK1197","BK0196"],"gpt_icon":0},{"id":"2600354810","title":"每周股票复盘：白云山（600332）注射用头孢呋辛钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2600354810","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600354810?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:03","pubTimestamp":1767290590,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，白云山报收于25.87元，较上周的25.72元上涨0.58%。本周，白云山12月23日盘中最高价报25.95元。近日，相关方已正式签署《合伙协议》，内容较此前公告无变更。广州白云山医药集团股份有限公司于2025年12月30日召开2025年第三次临时股东会，审议通过上述两项议案。该基金尚需办理工商注册登记及中国证券投资基金业协会登记备案手续，实施过程存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK1515","BK0175","BK0183","BK0188","BK0070","00874","BK0012","BK0097","BK1521","BK0096","BK1191","BK1197","BK1606","600332","BK0028"],"gpt_icon":0},{"id":"2600887000","title":"白云山附属企业广药二期基金正式签约设立广药荔湾基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2600887000","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600887000?lang=zh_cn&edition=full","pubTime":"2026-01-01 10:35","pubTimestamp":1767234911,"startTime":"0","endTime":"0","summary":"中访网数据 广州白云山医药集团股份有限公司于2025年12月31日发布公告，披露其附属企业广州广药二期基金股权投资合伙企业参与投资设立广州荔湾广药创业投资基金合伙企业的进展。根据公告，广药二期基金已与广州广药资本私募基金管理有限公司、广州天使投资母基金创业投资合伙企业及广州市荔湾区产业投资基金合伙企业正式签署《合伙协议》，标志着该投资基金进入实质设立阶段。根据此前董事会决议，广药二期基金的投资金额为9,950万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260101/31909956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","BK0096","BK0183","BK0188","BK0239","BK0175","600332","BK0028","00874","BK0070","BK1515","BK1521","BK1191","BK1606","BK0196","BK1197","BK0097"],"gpt_icon":0},{"id":"2595479215","title":"白云山：2025年第三次临时股东会决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2595479215","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595479215?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:39","pubTimestamp":1767098381,"startTime":"0","endTime":"0","summary":"证券日报网讯12月30日，白云山发布公告称，公司2025年12月30日召开2025年第三次临时股东会，审议通过《关于广州医药股份有限公司开展应收账款资产证券化业务的议案》《关于募集资金投资项目结项及节余募集资金永久补充流动资金的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605922236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","BK1521","BK0070","BK1197","BK0239","00874","600332","BK0012","BK1606","BK0188","BK1191","BK0096","BK0097","BK0183","BK1515","BK0175","BK0028"],"gpt_icon":0},{"id":"2595784972","title":"白云山(00874)：附属广药二期基金与广药资本、广开基金订立设立广药广开基金的合伙协议一","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784972","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784972?lang=zh_cn&edition=full","pubTime":"2025-12-29 19:02","pubTimestamp":1767006161,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，就有关本公司附属企业广药二期基金参与设立广药广开基金和广药荔湾基金的相关事宜。于2025年12月29日，广药二期基金与广药资本、广开基金订立了有关设立广药广开基金的合伙协议一。合伙协议一于同日正式生效，合伙协议一的主要条款并无任何变更。截至本公告日期，有关设立广药荔湾基金的合伙协议二尚未正式签署。本公司将根据香港上市规则的规定于合伙协议二签署后另行刊发公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600332","BK1191","BK1606","BK0070","BK0028","BK0175","BK0196","BK0012","BK1515","BK0239","00874","BK0188","BK1521","BK0096","BK1197","BK0183","BK0097"],"gpt_icon":0},{"id":"2595784352","title":"白云山最新公告：分公司白云山制药总厂注射用头孢呋辛钠通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784352","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784352?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:49","pubTimestamp":1767005395,"startTime":"0","endTime":"0","summary":"白云山公告称，公司分公司白云山制药总厂收到国家药品监督管理局签发的《药品补充申请批准通知书》，注射用头孢呋辛钠及注射用头孢呋辛钠通过仿制药质量和疗效一致性评价，并同意相关变更。头孢呋辛钠为第二代头孢菌素，临床广泛用于治疗呼吸道感染、泌尿系统感染及外科感染。该药品被列入国家基本药物目录和国家医保乙类品种。白云山制药总厂已投入研发费用约1,042.10万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900026894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0096","BK1606","00874","BK1515","BK0012","BK1521","01477","BK0188","BK0183","600332","BK0028","BK0097","BK1574","BK1197","BK0175","BK0070","BK0196","BK1191"],"gpt_icon":0},{"id":"2594247109","title":"每周股票复盘：白云山（600332）子公司获狂犬病疫苗注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2594247109","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594247109?lang=zh_cn&edition=full","pubTime":"2025-12-28 05:25","pubTimestamp":1766870713,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，白云山报收于25.87元，较上周的25.72元上涨0.58%。子公司广州白云山生物制品股份有限公司收到国家药品监督管理局核准签发的冻干人用狂犬病疫苗药品注册证书。该疫苗用于预防狂犬病，注册分类为预防用生物制品，药品批准文号有效期至2030年12月21日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600332","BK0096","00874","BK0188","BK1606","BK0028","BK1191","BK1521","BK0070","BK0183","BK0196","159646","BK0097","BK0175","BK1515","BK0239","BK1197","BK0012"],"gpt_icon":0},{"id":"2594681236","title":"白云山最新公告：旗下生物制品公司获冻干人用狂犬病疫苗注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2594681236","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594681236?lang=zh_cn&edition=full","pubTime":"2025-12-25 17:50","pubTimestamp":1766656209,"startTime":"0","endTime":"0","summary":"白云山(600332.SH)公告称，公司合并报表范围内企业白云山生物收到国家药品监督管理局核准签发的冻干人用狂犬病疫苗（Vero细胞）的《药品注册证书》。该疫苗用于预防狂犬病，白云山生物已投入约2.05亿元研发费用。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500026903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0012","BK0239","BK1197","BK0175","600332","BK0028","BK1515","BK0196","BK1191","BK0070","BK1521","BK1606","BK0097","BK0188","BK0183","00874","BK0096"],"gpt_icon":0},{"id":"2593343821","title":"白云山：第九届董事会第三十二次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2593343821","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593343821?lang=zh_cn&edition=full","pubTime":"2025-12-22 21:40","pubTimestamp":1766410803,"startTime":"0","endTime":"0","summary":"证券日报网讯12月22日晚间，白云山发布公告称，公司第九届董事会第三十二次会议审议通过《关于本公司2026年度日常关联交易预计数的议案》等多项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598566472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","BK0012","BK0188","BK1197","BK0096","00874","BK0183","BK0028","BK0239","BK1521","BK1191","BK0097","BK1515","BK0070","BK0175","600332","BK1606"],"gpt_icon":0},{"id":"1102865178","title":"白云山 - 子公司出资人民币9950万元参与建立GP荔湾基金","url":"https://stock-news.laohu8.com/highlight/detail?id=1102865178","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102865178?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:55","pubTimestamp":1766404512,"startTime":"0","endTime":"0","summary":"白云山 - 子公司出资人民币9950万元参与建立GP荔湾基金","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","600332","BK0183","BK1515","BK0097","BK1191","BK1521","BK0028","BK0070","BK0188","BK1197","BK0096","BK0175","BK0196","00874","BK1606","BK0239"],"gpt_icon":0},{"id":"1117819498","title":"白云山 - 参与设立广开基金和荔湾基金","url":"https://stock-news.laohu8.com/highlight/detail?id=1117819498","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117819498?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:55","pubTimestamp":1766404511,"startTime":"0","endTime":"0","summary":"白云山 - 参与设立广开基金和荔湾基金","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0070","BK0188","BK0097","BK0239","BK0096","BK0028","BK0012","BK0175","BK0196","600332"],"gpt_icon":0},{"id":"2593548484","title":"白云山最新公告：附属企业拟投资9750万元认购广药广开基金有限合伙份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2593548484","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593548484?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:30","pubTimestamp":1766403045,"startTime":"0","endTime":"0","summary":"白云山(600332.SH)公告称，公司附属企业广药二期基金拟投资9750万元认购广药广开基金有限合伙份额，占广药广开基金认缴出资总额的48.75%。广药资本作为执行事务合伙人、基金管理人和普通合伙人认缴出资250万元。公司副董事长程宁女士担任广药资本的董事长，因此本次投资构成关联交易。本次投资不构成重大资产重组。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200026407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0239","BK0070","BK1197","BK0012","BK0096","BK0175","BK1521","BK0196","BK0097","BK0028","BK1515","600332","BK1191","BK1606","00874","BK0188"],"gpt_icon":0},{"id":"1191245448","title":"白云山 - 旗下单位将以5.005亿人民币收购浙江医药产业100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1191245448","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191245448?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:48","pubTimestamp":1765982892,"startTime":"0","endTime":"0","summary":"白云山 - 旗下单位将以5.005亿人民币收购浙江医药产业100%股权","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0012","BK0188","BK1191","BK1521","BK0028","BK0196","BK1197","BK1606","BK1515","00874","BK0070","BK0096","600332","BK0175","BK0183","BK0097"],"gpt_icon":0},{"id":"2592916198","title":"白云山（600332）披露控股子公司拟开展应收账款资产证券化业务，12月17日股价上涨0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592916198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592916198?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:42","pubTimestamp":1765982548,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，白云山报收于25.66元，较前一交易日上涨0.12%，最新总市值为417.18亿元。该股当日开盘25.54元，最高25.7元，最低25.46元，成交额达2.7亿元，换手率为0.75%。近日，广州白云山医药集团股份有限公司发布关于2025年第三次临时股东会会议资料的公告。公告显示，公司拟审议一项重要议案：控股子公司广州医药拟开展应收账款资产证券化业务，融资规模不超过30亿元，期限不超过2年。该事项旨在拓宽融资渠道、优化资金结构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700040340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0070","BK0188","BK0097","00874","BK1606","BK0239","BK0096","BK0028","BK0012","BK1515","BK1197","BK1191","BK0175","BK0196","600332","BK1521"],"gpt_icon":0},{"id":"2592991261","title":"白云山最新公告：子公司广州医药拟5.005亿元收购浙江医工100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2592991261","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592991261?lang=zh_cn&edition=full","pubTime":"2025-12-17 19:19","pubTimestamp":1765970393,"startTime":"0","endTime":"0","summary":"白云山(600332.SH)公告称，公司下属控股子公司广州医药与浙江海正药业签署股权交易合同及补充协议，广州医药拟通过公开摘牌方式受让海正药业所持浙江省医药工业有限公司100%股权，转让价款为5.005亿元。本次收购不构成关联交易，不构成重大资产重组，但需通过中国反垄断审查机构进行经营者集中审查，交易尚存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700031414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1521","BK0070","BK1161","BK0097","BK1515","00874","BK0239","BK1574","BK0028","159938","BK0012","BK0096","BK1191","BK1606","BK0183","BK1197","600332","BK0175","BK0188","09939","BK0196"],"gpt_icon":0},{"id":"2591648052","title":"小摩减持白云山(00874)11.2万股 每股作价18.581港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648052","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591648052?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:58","pubTimestamp":1765796294,"startTime":"0","endTime":"0","summary":"减持后最新持股数目约为1969.23万股，最新持股比例为8.95%。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20251215/20251215185837_22361.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251215/20251215185837_22361.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0942090050.USD","LU2746668461.USD","LU2381873111.SGD","IE00BLSP4239.USD","LU0868494617.USD","BK4516","BK1515","LU0215105999.USD","600332","BK4207","IE00BYXW3230.USD","LU1116320737.USD","IE00BZ1G4Q59.USD","IE00BBT3K403.USD","LU0345769631.USD","LU2023250843.SGD","LU0251132253.USD","LU1244550494.USD","LU2237443622.USD","IE00BDRTCR15.USD","LU2746668974.SGD","LU1551013342.USD","LU2417539215.USD","LU1629891620.HKD","BK1191","LU1496350502.SGD","LU1894683264.USD","LU1894683348.USD","LU2430703251.USD","LU0820561818.USD","LU2237443978.SGD","LU0170899867.USD","LU1914381329.SGD","LU1988902786.USD","LU2552382058.USD","BK1521","BK0239","IE00BLSP4452.SGD","LU2462157665.USD","LU0203345920.USD","LU1496350171.SGD","00874","LU1116320901.HKD","BK0183","LU0234572021.USD","LU2756315318.SGD","IE00BWXC8680.SGD","BK1606","BK4534","LU0971096721.USD"],"gpt_icon":0},{"id":"2591610368","title":"白云山（600332）披露子公司《药品生产许可证》注销公告，12月15日股价下跌1.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591610368","media":"中金财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591610368?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:19","pubTimestamp":1765793980,"startTime":"0","endTime":"0","summary":"近日，广东省药品监督管理局发布通告，广州白云山医药集团股份有限公司子公司广州白云山星珠药业有限公司的《药品生产许可证》已注销。本次注销原因为星珠药业进行生产经营业务调整，在生产范围为中药饮片的《药品生产许可证》有效期届满后不再申请重新发证。星珠药业2024年中药饮片业务未产生营业收入，本次注销对其生产经营无影响，对公司当期业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251215/31866395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0183","BK0097","BK0239","00874","BK1197","BK1606","BK0175","BK0096","BK1515","BK0070","BK0188","BK0012","BK0196","BK1521","600332","BK0028","BK1191"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768452768493,"stockEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.023},{"period":"3month","weight":-0.0241},{"period":"6month","weight":-0.0487},{"period":"1year","weight":-0.0494},{"period":"ytd","weight":-0.0249}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0667},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.2731},{"period":"ytd","weight":0.0396}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州白云山医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2001-02-06","address":"广东省广州市荔湾区沙面北街45号","registeredCapital":"162579万元","survey":" 广州白云山医药集团股份有限公司的主营业务是中西成药、化学原料药、天然药物、生物医药、化学原料药中间体的研发、制造与销售；西药、中药和医疗器械的批发、零售和进出口业务；大健康产品的研发、生产与销售；医疗服务、健康管理、养生养老等健康产业投资。公司的主要产品是中成药、化学药。","listedPrice":9.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"白云山(600332)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供白云山(600332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"白云山,600332,白云山股票,白云山股票老虎,白云山股票老虎国际,白云山行情,白云山股票行情,白云山股价,白云山股市,白云山股票价格,白云山股票交易,白云山股票购买,白云山股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"白云山(600332)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供白云山(600332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}